Related Experiment Video

Updated: May 27, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Initiation of statin therapy: are there age limits?

Dipan A Desai1, Sammy Zakaria, Pamela Ouyang

  • 1Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Johns Hopkins Bayview Medical Center, 4940 Eastern Ave, 301 Building, Suite 2400, Baltimore, MD 21224, USA.

Current Atherosclerosis Reports
|November 17, 2011
PubMed

Insights

Statin therapy benefits older adults for cardiovascular disease (CVD) prevention, but evidence for those 80+ is limited. Clinical judgment is crucial for initiating statins in this age group.

Area of Science:

  • Gerontology
  • Cardiology
  • Pharmacology

Background:

  • Cardiovascular disease (CVD) is a leading cause of death, disproportionately affecting older adults.
  • Statin therapy is proven effective for CVD prevention in middle-aged adults.
  • Limited research exists on statin efficacy and safety in adults aged 80 years and older.

Purpose of the Study:

  • To review current literature on primary and secondary CVD prevention using statin therapy in older adults.
  • To discuss the applicability and limitations of CVD risk scores in the elderly population.
  • To evaluate the benefits, risks, and cost-effectiveness of statin use in adults aged 80+.

Main Methods:

  • Systematic review of recent publications on statin therapy for CVD prevention in older adults.
  • Analysis of CVD risk assessment tools and their limitations in elderly populations.
  • Examination of adverse effects, drug interactions, and cost-effectiveness of statins in this demographic.

Main Results:

  • Statin therapy shows potential for CVD risk reduction in older adults.
  • Risk scores may be less reliable in older individuals.
  • Adverse effects and drug interactions with statins can be more pronounced in the elderly.
  • Cost-effectiveness is contingent on risk stratification and assumptions used.

Conclusions:

  • Evidence for initiating statin therapy in adults aged 80 years and older remains limited.
  • Careful clinical judgment is essential when considering statins for very old adults.
  • Further research is needed to establish definitive guidelines for statin use in the oldest populations.

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution01:00

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution

Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are not...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...